We describe key mechanisms and applications of NATs, review pre-clinical and clinical examples of NATs as differentiation agents in myeloid leukemias, and provide NAT design and delivery strategies to modulate relevant AML therapeutic targets. This evidence concerns the gene BRD2 and myeloid leukemia.